Vedolizumab is superior to infliximab in biologic naïve patients with ulcerative colitis

There are no prospective, head-to-head, controlled trials comparing the efficacy and safety of Infliximab (IFX) and Vedolizumab (VDZ) for the treatment of moderate-to-severe ulcerative colitis (UC), while only a few real-life retrospective studies have been published so far. We assessed the efficacy...

Descripción completa

Detalles Bibliográficos
Autores principales: Sablich, Renato, Urbano, Maria Teresa, Scarpa, Marco, Scognamiglio, Federico, Paviotti, Alberto, Savarino, Edoardo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2023
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9892496/
https://www.ncbi.nlm.nih.gov/pubmed/36725872
http://dx.doi.org/10.1038/s41598-023-28907-3

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9892496/
https://www.ncbi.nlm.nih.gov/pubmed/36725872
http://dx.doi.org/10.1038/s41598-023-28907-3

Ejemplares similares